CMS signals plans to increasingly rely on coverage with evidence development (CED) in a final guidance that backs away from an earlier expectation that the agency would only use the policy infrequently as new technologies were presented for coverage early in the development process. The agency also reiterates that it will neither duplicate efforts by other agencies such as FDA nor duplicate existing medical evidence; and that national coverage determinations (NCD) can be expedited by building interim analysis into a...